About uniqure n.v. - QURE
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.
QURE At a Glance
uniQure NV
Paasheuvelweg 25a
Amsterdam, Noord-Holland 1105 BP
| Phone | 31-20-240-60-00 | Revenue | 16.10M | |
| Industry | Biotechnology | Net Income | -198,971,000.00 | |
| Sector | Health Technology | Employees | 221 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
QURE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 85.478 |
| Price to Book Ratio | 7.50 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.557 |
| Enterprise Value to Sales | 80.139 |
| Total Debt to Enterprise Value | 0.416 |
QURE Efficiency
| Revenue/Employee | 72,841.629 |
| Income Per Employee | -900,321.267 |
| Receivables Turnover | 2.746 |
| Total Asset Turnover | 0.023 |
QURE Liquidity
| Current Ratio | 10.426 |
| Quick Ratio | 10.426 |
| Cash Ratio | 9.894 |
QURE Profitability
| Gross Margin | -2.156 |
| Operating Margin | -1,152.131 |
| Pretax Margin | -1,201.019 |
| Net Margin | -1,235.998 |
| Return on Assets | -28.806 |
| Return on Equity | -207.101 |
| Return on Total Capital | -27.053 |
| Return on Invested Capital | -32.558 |
QURE Capital Structure
| Total Debt to Total Equity | 269.778 |
| Total Debt to Total Capital | 72.957 |
| Total Debt to Total Assets | 65.049 |
| Long-Term Debt to Equity | 267.837 |
| Long-Term Debt to Total Capital | 72.432 |